Clinical trials: Advanced/Recurrent Ovarian Cancer
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Ovarian Cancer
Carboplatin With or Without Gemcitabine in Treating Patients With Advanced Ovarian Epithelial Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006453
- Testing
- carboplatin, gemcitabine hydrochloride
- Where
- 74 sites in United States, Canada
- Sponsor
- AGO Study Group
Ovarian Cancer, Peritoneal Cancer
PH I SRC Kinase, Dasatinib Combo Paclitaxel & Carboplatin in Pts w Ovarian, Peritoneal, & Tubal Cancer
Primary objective to determine the maximal tolerated (MTD) of dasatinib in combination with paclitaxel and carboplatin during the first cycle of treatment.
- Conditions
- Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00672295
- Testing
- Dasatinib, Paclitaxel, and Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- AA Secord
Ovarian Cancer, Endometrial Cancer
A Phase 2 Study of Oral MKC-1 in Patients With Ovarian or Endometrial Cancer
Patients will be treated with MKC-1, twice daily for 14 consecutive days every four weeks (a cycle of MKC-1 chemotherapy), until disease progression or unacceptable toxicities.
- Trial name
- NCT00607607
- Testing
- MKC-1
- Where
- 6 sites in Canada
- Volunteers
- 44 people
- Sponsor
- CASI pharmaceuticals, Inc.
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
This phase I trial studies the side effects and best dose of ziv-aflibercept when given together with pembrolizumab in treating patients with solid tumors that that may have spread from where it first started to nearby tissue…
- Conditions
- Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma
- Trial name
- NCT02298959
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 9 sites in United States, Canada
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Ovarian Cancer
A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant Tumors
The study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic cervical cancer or ovarian cancer failed or…
- Trial name
- NCT06769152
- Testing
- HLX43
- Where
- China
- Volunteers
- 190 people
- Sponsor
- Shanghai Henlius Biotech
Adrenocortical Carcinoma, Breast Cancer
Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer
RATIONALE: Biological therapies, such as tumor necrosis factor, may stimulate the immune system in different ways and stop tumor cells from growing.
- Conditions
- Adrenocortical Carcinoma, Breast Cancer, Colorectal Cancer, Gastrointestinal Cancer
- Trial name
- NCT00436410
- Testing
- colloidal gold-bound tumor necrosis factor, electron microscopy, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 108 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer
Phase I trial to study the effectiveness of interleukin-12 in treating patients with refractory ovarian or abdominal cancers. Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a persons's…
- Trial name
- NCT00003439
- Testing
- recombinant interleukin-12
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Malignant Mesothelioma, Carcinoma of the Appendix
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
RATIONALE: An orientation and patient education program and telephone counseling may help improve the quality of life in patients with peritoneal surface malignancies.
- Conditions
- Advanced Malignant Mesothelioma, Carcinoma of the Appendix, Ovarian Sarcoma, Ovarian Stromal Cancer
- Trial name
- HOPE (NCT01126346)
- Testing
- HIPEC Orientation, Consultation with Survivorship Navigator, Questionnaires
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Endometrial Cancer, Ovarian Cancer
Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have advanced…
- Conditions
- Endometrial Cancer, Ovarian Cancer, Sarcoma
- Trial name
- NCT00003718
- Testing
- temozolomide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Fallopian Tube Cancer, Ovarian Cancer
TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in treating patients who have advanced ovarian…
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00022347
- Testing
- canfosfamide hydrochloride
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced or Recurrent Solid Tumors, Breast Neoplasms
Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
This is a single-arm, open-label study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of talazoparib in patients with advanced tumors with DNA-repair pathway deficiencies.
- Conditions
- Advanced or Recurrent Solid Tumors, Breast Neoplasms, Ovarian Cancer, Epithelial, Ewing Sarcoma
- Trial name
- NCT01286987
- Testing
- Talazoparib
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 113 people
- Sponsor
- Pfizer
Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma
Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma
This is a phase 1 dose escalation study to characterize the feasibility, safety and tolerability of MCY-M11 when administered as an intraperitoneal (IP) infusion for 3 weekly doses for women with platinum resistant high grade…
- Conditions
- Peritoneal Mesothelioma, Fallopian Tube Adenocarcinoma, Adenocarcinoma of the Ovary, Primary Peritoneal Carcinoma
- Trial name
- NCT03608618
- Testing
- MCY-M11, Cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- MaxCyte, Inc.
HER2-positive Breast Cancer, Recurrent Breast Cancer
Cyclophosphamide or Denileukin Diftitox Followed By Expanding a Patient's Own T Cells in the Laboratory in Treating Patients With HER-2/Neu Overexpressing Metastatic Breast Cancer, Ovarian Cancer, or Non-Small Cell Lung Cancer Previously Treated With HER-2/Neu Vaccine
This phase I trial studies the safety and the ability to expand laboratory-treated T cells when given together with cyclophosphamide or denileukin diftitox in treating patients with human epidermal growth factor receptor…
- Conditions
- HER2-positive Breast Cancer, Recurrent Breast Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer
- Trial name
- NCT00228358
- Testing
- ex vivo-expanded HER2-specific T cells, cyclophosphamide, denileukin diftitox
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of Washington
Breast Cancer, Ovarian Cancer
Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have metastatic…
- Conditions
- Breast Cancer, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- BMS-247550 (NCT00005807)
- Testing
- BMS-247550
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Albert Einstein College of Medicine
Ovarian Neoplasms
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
Most ovarian cancer will relapse after standard therapy. Patients with recurrent ovarian cancer are resistant to platinum. Due to the high heterogeneity between ovarian cancer, individual precise therapy is of great importance.
- Trial name
- NCT05290961
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Chongqing University Cancer Hospital
Bladder Cancer, Brain and Central Nervous System Tumors
Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer
- Trial name
- NCT00313599
- Testing
- lapatinib, paclitaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Ovarian Cancer
Aminocamptothecin in Treating Patients With Recurrent or Unresectable Epithelial Ovarian Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of aminocamptothecin in treating patients with recurrent…
- Trial name
- NCT00002671
- Testing
- aminocamptothecin
- Where
- 6 sites in United States
- Sponsor
- NYU Langone Health
Colorectal Neoplasms, Breast Neoplasms
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
Background: Durvalumab is a drug that may help people s immune systems respond to and kill cancer cells. Olaparib is a drug that may inhibit repairing DNA damage of cancer cells.
- Trial name
- NCT02484404
- Testing
- Olaparib, Cediranib, Durvalumab
- Where
- United States
- Volunteers
- 268 people
- Sponsor
- National Cancer Institute (NCI)